Evidence map›Paper›PMID 32868801›Full record

ArticleScientific reports2020

Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.

Hye Jin Jeong, Sein Min, Heelim Chae, Sarah Kim, Gunwoo Lee, Sung Keon Namgoong, Keunhong Jeong

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hye Jin JeongDepartment of Chemistry, Korea Military Academy, Seoul, 01805, South Korea.
Sein MinDepartment of Chemistry, Seoul Women's University, Seoul, 01797, South Korea.
Heelim ChaeDepartment of Chemistry, Seoul Women's University, Seoul, 01797, South Korea.
Sarah KimDepartment of Chemistry, Seoul Women's University, Seoul, 01797, South Korea.
Gunwoo LeeDepartment of Chemistry, Korea Military Academy, Seoul, 01805, South Korea.
Sung Keon NamgoongDepartment of Chemistry, Seoul Women's University, Seoul, 01797, South Korea.
Keunhong JeongDepartment of Chemistry, Korea Military Academy, Seoul, 01805, South Korea. doas1mind@kma.ac.kr.
Seoul Women's University · KRKorea Military Academy · KR

Funding

National Research Foundation of Korea No. 2020R1C1C1007888
6 · The paper itself

Abstract

Several drug candidates have been proposed and tested as the latest clinical treatment for coronavirus pneumonia (COVID-19). Chloroquine, hydroxychloroquine, ritonavir/lopinavir, and favipiravir are under trials for the treatment of this disease. The hyperpolarization technique has the ability to further provide a better understanding of the roles of these drugs at the molecular scale and in different applications in the field of nuclear magnetic resonance/magnetic resonance imaging. This technique may provide new opportunities in diagnosis and research of COVID-19. Signal amplification by reversible exchange-based hyperpolarization studies on large-sized drug candidates were carried out. We observed hyperpolarized proton signals from whole structures, due to the unprecedented long-distance polarization transfer by para-hydrogen. We also found that the optimal magnetic field for the maximum polarization transfer yield was dependent on the molecular structure. We can expect further research on the hyperpolarization of other important large molecules, isotope labeling, as well as polarization transfer on nuclei with a long spin relaxation time. A clinical perspective of these features on drug molecules can broaden the application of hyperpolarization techniques for therapeutic studies.

Indexed as

Drug DiscoveryAmidesAntiviral AgentsBetacoronavirusChloroquineCoronavirus InfectionsCOVID-19HumansLopinavirMolecular StructureNuclear Magnetic Resonance, BiomolecularPandemicsPneumonia, ViralPyrazinesRitonavirSARS-CoV-2AmidesAntiviral AgentsChloroquinefavipiravirLopinavirPyrazinesRitonavir

Identifiers

PMID32868801
PMCPMC7459298
OpenAlexW3082854305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.